ABT
Same stock, slightly smaller halo
JPMorgan just nudged Abbott Laboratories’ price target down to $110 from $123, while sticking with an Overweight rating. Translation: they still like the name, just not quite as much as before. That’s the kind of Wall Street move that says, “You’re fine, but don’t get too comfy.”
Why the target got shaved
This comes in the middle of a busy post-earnings cleanup tour for Abbott. The company posted a modest Q1 beat — EPS of $1.15 vs. $1.14 expected, and revenue of $11.16 billion vs. $10.99 billion — but then lowered its FY2026 and Q2 outlook. Investors were already grumpy about the roughly $0.20 EPS dilution from the Exact Sciences acquisition, so even a decent beat couldn’t fully save the vibe.
The analyst crowd isn’t bailing, just recalculating
JPMorgan isn’t alone here. Other firms have also trimmed targets, which is basically the market’s way of saying, “Nice quarter, but we’ve adjusted the math.” Still, coverage remains broadly constructive, with Abbott sitting around a Moderate Buy consensus and an average target near $121.
Big picture: still a favorite, just with less swagger
For investors, the key thing is that this isn’t a thesis wrecking ball. Abbott still has bullish coverage, but the easy upside got a little harder to see after the guidance cut and acquisition dilution. Big picture: the stock may still work, but the path looks more like a staircase than a rocket ship.